Drugs Dosage Side effects Drug interactions Comments
Amphotericin B 0.7–1.0 mg/kg/d
3–6 mg/kg/d (liposomal)
5 mg/kg/d (lipid complex)
Immediate hypersensitivity reaction, fever, hypotension, nausea and vomiting during administration, hypokalemia, and nephrotoxicity Nephrotoxic drugs (e.g., aminoglycosides, pentamidine, foscarnet, cidofovir) Liposomal or lipid complex formulation should be considered in patients with renal dysfunction
Flucytosine (5-FC) 25 mg/kg q6h Gastrointestinal, bone marrow suppression Nephrotoxic drugs Dosage must be reduced in patients with renal dysfunction; drug level should be monitored
Fluconazole 400 mg/d (acute therapy), 200 mg/d (suppressive therapy) Nausea, rash, and hepatitis Rifabutin (increased rifabutin levels); rifampin (decreased fluconazole levels) Dosage may need to be adjusted in renal dysfunction
Itraconazole 200–400 mg BID Nausea, abdominal pain, rash, headache, edema, and hypokalemia Rifamycins, ritonavir, phenobarbitol, phenytoin all decrease itraconazole levels
The effect of nevirapine is unknown; the drug should not be used concomitantly with terfenadine or astemizole
Antacids, histamine blockers decrease itraconazole absorption
Itraconazole itself acts as a moderate inhibitor of cytochrome P450 system and can increase levels of indinavir, cyclosporin, digoxin, and phenytoin
Absorption of itraconazole is dependent on food and gastric acid and may be erratic; the newer solution is better absorbed

Cryptococcal infection in normal hosts

Untreated cryptococcal meningitis is uniformly fatal, so all patients with meningitis must be treated. Most of the available evidence suggests that amphotericin B-based therapy remains the gold standard and the combination of an amphotericin B preparation plus flucytosine (5-FC) should be regarded as the best initial treatment. Recent studies indicate that this combination is most likely to lead to more effective and more rapid clearance of the fungus from the CSF, which is probably the best surrogate marker for ultimate successful therapy. This conceptual approach is consistent with clinical trial data in AIDS that amphotericin B-based therapy is superior to initial therapy with azoles. The different amphotericin B preparations have not been shown to have important differences in response rates of cryptococcal meningitis, although clearly the lipid-based formulations are less toxic than amphotericin B deoxycholate. Because some degree of nephrotoxicity is inevitable if amphotericin B deoxycholate is given for 4 to 6 weeks, current recommendations suggest that liposomal amphotericin at a dose of 5 mg/kg is the preferred treatment for cryptococcal meningitis in normal hosts. Although it is unclear whether 5-FC is necessary in normal hosts, extrapolation from trials in patients with AIDS would suggest that it accelerates clearance of the fungus and improves mortality. The recommended dosage is 37.5 mg/kg four times daily. Levels must be measured to minimize toxicity (especially bone marrow suppression), and dosages must be adjusted for renal insufficiency.

The duration of therapy is not well defined for patients with cryptococcal infection. Normal subjects with no evident risk factors for a poor outcome respond well to 4 weeks of combination therapy, and this is often curative. Prolonged therapy should be considered for patients at risk of relapse (Table 176.2). Pulmonary cryptococcosis without meningeal involvement can be treated initially with fluconazole. However, for meningitis, there is no controlled trial of fluconazole, especially comparing initial azole therapy with an amphotericin B-based regimen. With current data, amphotericin B plus 5-FC is still recommended as standard therapy for cryptococcal meningitis. Fluconazole can be used to treat patients (or to complete a course of treatment in patients) who cannot tolerate amphotericin B or patients without neurological involvement. In many circumstances (need for intravenous access, difficulties with outpatient parenteral therapy, toxicity) a full course of parenteral amphotericin B is impractical or undesirable, and a switch to fluconazole is preferred. Timing of such a switch is uncertain. There is insufficient evidence to advocate using changes in cryptococcal antigen as a guide to making treatment decisions, but it is probably reasonable to consider using the clearance of yeast from CSF as an indicator for switching treatment from polyene to oral azole therapy. In most patients, this is likely to take 2 to 3 weeks to achieve, suggesting this is probably the minimum amount of amphotericin B therapy that should be used.

Table 176.2 Factors predicting relapse of cryptococcal meningitis

Presentation with neurologic abnormalities
CSF leukocyte count 20 cells/mm3
CSF antigen titer >1:32
Positive India ink stain after 4 wk of treatment
CSF antigen titer greater than 1:8 after 4 wk of treatment

Abbreviation: CSF = cerebrospinal fluid.

Once patients have been switched to fluconazole, the next question becomes how long to treat? Unfortunately, there are absolutely no well-controlled studies to answer this question. Given the potential severity of cryptococcal infection, the most prudent recommendation would be to treat with fluconazole for 6 to 12 months after clearance of CSF has been documented.

Cryptococcal infection in AIDS

In patients with AIDS, the acute mortality with cryptococcal meningitis ranges from 10% to 25%. Multiple clinical factors have been identified in studies as predictors of a poor outcome, as summarized in Table 176.3

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jun 18, 2016 | Posted by in INFECTIOUS DISEASE | Comments Off on Cryptococcus

Full access? Get Clinical Tree

Get Clinical Tree app for offline access